Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Malaria

- PMLiVE

UK scientists reveal promising new treatment strategy for acute myeloid leukaemia

The aggressive form of blood cancer is responsible for more than 3,000 new cases in the UK every year

- PMLiVE

Scientists to develop vaccine to prevent lung cancer following £1.7m grant

Lung cancer is responsible for over 48,000 cases in the UK every year

- PMLiVE

New blood test could identify individuals at highest risk of developing heart failure

Measuring NPY alongside BNP could help healthcare professionals improve diagnosis for heart patients

dengue fever mosquito

Positive efficacy results for R21/Matrix-M malaria vaccine published in The Lancet

R21 was added to the World Health Organization's list of prequalified vaccines in December

- PMLiVE

Study finds vaccination against COVID-19 reduces long COVID symptoms

The results could help inform public health strategies and vaccination campaigns

- PMLiVE

World Health Organization adds second malaria vaccine to prequalification list

The addition is expected to result in sufficient malaria vaccine supply for children

Can Cinderella save us?

Study finds AI detects AMR faster than gold-standard testing

The method detected AMR with at least 80% accuracy on a per-cell basis, within 30 minutes

- PMLiVE

University of Oxford launches new trial to enhance flu and COVID-19 vaccines

Results from the study are expected to help increase the protection of future vaccines

- PMLiVE

WHO recommends second malaria vaccine for children

The addition of R21/Matrix-M to the organisation’s list is expected to result in sufficient malaria vaccine supply

- PMLiVE

New UK study suggests brain fog after COVID-19 is linked to blood clots

High levels of two proteins caused excess blood clotting in people with long COVID

- PMLiVE

New screening model shown to predict ten year breast cancer mortality risk

The risk-based screening model works to identify those at the highest risk of cancer

- PMLiVE

Vironix and Oxford University partner to advance chronic kidney disease monitoring

The partners will aim to develop learning models that predict the progression of CKD

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links